Ranee Mehra

PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

J. Weiss, John Kaczmar, Ashish Chintakuntlawar, MD Francis P. Worden et autres

Importance: The incidence of human papillomavirus type 16 (HPV16-positive) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is rising. Approved therapies offer a durable response to a minority of patients. Objective: To determine the efficacy and safety of a therapeutic HPV16-targeted …

us, gb, ie (code pays fourni par la source)

Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study

Hsiang‐Fong Kao, Kevin J. Harrington, Aarti Bhatia, Hung‐Ming Wang et autres

BACKGROUND: Prognosis is poor for patients with recurrent/metastatic (R/M) head and neck squamous cell cancer (HNSCC), warranting novel treatments. Epidermal growth factor receptor (EGFR) and MET are overexpressed in HNSCC and contribute to cancer progression and metastasis. Amivantamab, an EGFR-MET bispecific antibody, …

tw, gb, ca, us, my, pl, es, kr, br, nl (code pays fourni par la source)

Tumor genomic alterations and their exploratory association with treatment response in recurrent head and neck cancer patients

Olive Beyer, Andrey Loginov, Danielle Arons, Erin Allor et autres

Abstract While the genetic landscape of treatment-naïve head and neck squamous cell carcinoma (HNSCC) is well characterized, the molecular features of recurrent disease remain less defined. We investigated the genetic alterations in recurrent HNSCC and their associations with overall survival (OS), progression-free …

us (code pays fourni par la source)

Nurse Navigation on Time to Postoperative Radiation Therapy after Transoral Robotic Surgery for Oropharyngeal Carcinoma

Vera Bzhilyanskaya, Jane Y. Tong, Theresa Vetter‐Habighorst, Kelly Moyer et autres

OBJECTIVE: Postoperative radiation therapy (PORT) initiation within 6 weeks of surgery is associated with improved oncologic outcomes in head and neck cancer, but delays remain common. Oncology nurse navigators (ONN) may improve care coordination. This study evaluates time to PORT following transoral …

us (code pays fourni par la source)

Impact of Radiomics Parameters and Clinical Integration on Prognostication in Head and Neck Squamous Cell Carcinoma: A Multicenter Study

Hajar Moradmand, Jason Molitoris, Ranee Mehra, Lisa M. Schumaker et autres

Radiomics has the potential to improve risk stratification in head and neck squamous cell carcinoma (HNSCC), but clinical adoption is limited by inconsistent performance across institutions. A key source of variability is how radiomic features are generated, preprocessed, and selected prior to …

us (code pays fourni par la source)

Predictive markers of response and toxicity to tarlatamab in patients with extensive stage small cell lung cancer (ES-SCLC): A multi-institutional real-world analysis.

Graeme Fenton, Daniel Hess, Annie Zhang, Wanru Guo et autres

8097 Background: Tarlatamab (tarla) is a novel immunotherapeutic agent for the treatment of relapsed ES-SCLC associated with favorable response and survival outcomes. While tarla’s unique side effect profile of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) is well …

us (code pays fourni par la source)

Historical redlining and oral squamous cell carcinoma staging at diagnosis.

Pei‐Lun Kuo, Lisa Mary Schumaker, Olive Beyer, Raquel Rowell et autres

e22598 Background: Previous research has shown that residents in historically redlined zones, areas defined from the discriminatory housing policy in 1935-1940, are more prone to being diagnosed with later-stage cancer for breast cancer, cervical cancer, lung cancer, colorectal cancer, and prostate cancer. …

us (code pays fourni par la source)

Phase 1 first-in-human trial of AG01, a recombinant humanized monoclonal antibody to progranulin/glycoprotein 88 (GP88) to determine the safety, tolerability, pharmacokinetics, and preliminary antitumor activity in subjects with advanced solid tumor malignancies.

Katherine Tkaczuk, Katherine A. Scilla, Gautam G. Rao, Yixing Jiang et autres

TPS2669 Background: Progranulin also called GP88/PGRN plays a major role as an autocrine growth & survival factor associated with resistance to standard of care (SOC) targeted and chemo therapies in several cancers including breast cancer (BC) & non-small cell lung carcinoma (NSCLC): …

us (code pays fourni par la source)

High frequency of RB1 mutations p16 positive early stage oropharyngeal carcinoma: A genomic and transcriptomic analysis

Matthew H. Brown, William S. Mendes, Yang Song, Amol C. Shetty et autres

us (code pays fourni par la source)

Effect of Smoking in Oropharyngeal Cancer Treated With TORS : Systematic Review and Meta‐Analysis

Jane Y. Tong, Neha Amin, Cailin Cruess, Emilie Ludeman et autres

OBJECTIVE: While smoking has been implicated as a risk factor for recurrence in HPV-associated oropharyngeal squamous cell cancer (OPSCC) treated with definitive chemoradiation, its prognostic impact on surgically treated OPSCC is less clear. DATA SOURCES: MEDLINE, Embase, CENTRAL, and Scopus. REVIEW METHODS: …

us (code pays fourni par la source)

Does Smoking Influence Outcomes in Human Papillomavirus—Associated Oropharyngeal Cancer Treated with Transoral Robotic Surgery?

Jane Y. Tong, Vera Bzhilyanskaya, Jason K. Molitoris, Matthew J. Ferris et autres

OBJECTIVE: Smoking has been identified as a risk factor for recurrence in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) treated with definitive chemoradiation. Whether the same prognostic significance holds with surgical treatment such as transoral robotic surgery (TORS) is less well studied. STUDY …

us (code pays fourni par la source)

Brief Report: Multi-Institution Real-World Analysis Evaluating Safety, Efficacy, and ctDNA Dynamics After Tarlatamab in Patients With Previously Treated SCLC and LCNEC

Graeme Fenton, Annie L. Zhang, Sharon Zhong, Curtis Tatsuoka et autres

Tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3 and CD3 on T cells, has generated impressive treatment response rates in relapsed extensive-stage SCLC and large cell neuroendocrine carcinoma. We performed a retrospective, multi-institutional analysis of 48 patients who received tarlatamab as …

us (code pays fourni par la source)